Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Duality Biotherapeutics, Inc. ( (HK:9606) ) just unveiled an update.
Duality Biotherapeutics said China’s National Medical Products Administration has accepted its Biologics License Application for DB-1303/BNT323 to treat adults with unresectable or metastatic HER2-positive breast cancer, following positive Phase III trial data versus T-DM1. The pivotal study met its primary endpoint of progression-free survival with statistically significant and clinically meaningful benefit and a favorable safety profile, potentially positioning DB-1303 as a new treatment option in a competitive HER2 oncology market and underscoring the strategic value of the company’s ADC platform across multiple tumor types.
DB-1303/BNT323, also known as trastuzumab pamirtecan and co-developed with BioNTech, is being evaluated in global pivotal trials for HER2-low, hormone receptor–positive metastatic breast cancer and advanced endometrial cancer, as well as in novel combination regimens. The candidate has secured Fast Track and Breakthrough Therapy designations in the U.S. and Breakthrough Therapy designation in China for HER2-expressing advanced endometrial cancer, reflecting regulatory confidence that may accelerate development timelines and enhance Duality’s competitive footing in oncology therapeutics.
The most recent analyst rating on (HK:9606) stock is a Buy with a HK$383.47 price target. To see the full list of analyst forecasts on Duality Biotherapeutics, Inc. stock, see the HK:9606 Stock Forecast page.
More about Duality Biotherapeutics, Inc.
Duality Biotherapeutics, Inc. is a Cayman Islands–incorporated biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) and other innovative oncology therapies. Its core pipeline includes DB-1303/BNT323, a HER2-targeting ADC built on its proprietary DITAC platform, aimed at treating a range of HER2-expressing and HER2-low solid tumors in major global markets.
Average Trading Volume: 814,513
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$28.01B
For detailed information about 9606 stock, go to TipRanks’ Stock Analysis page.